Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

Mediterranean Journal of Hematology and Infectious Diseases 2026 Open access

Read full text
Authors: Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi
DOI: 10.4084/mjhid.2026.009
Cited by: 0

Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are low-grade non-Hodgkin lymphomas characterized by monoclonal B lymphocytes. Bruton tyrosine kinase inhibitors represent the first-line treatment for symptomatic CLL/SLL. Here we report a case of a patient with SLL treated with ibrutinib who developed macular edema as confirmed by optical coherence tomography.

Fields of Study & Subjects

Chronic Lymphocytic Leukemia Research Drug-Induced Ocular Toxicity Chronic Myeloid Leukemia Treatments

Publication details

Journal / source
Mediterranean Journal of Hematology and Infectious Diseases
Volume
18
Issue
1
Pages
e2026009–e2026009
Publication date
1 January 2026
Language
EN